ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients June 7, 2018
Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL June 7, 2018
Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery identify HBV cccDNA inhibitors June 7, 2018
Shandong Luoxin Pharmacy Group, Luoxin Biotechnology Shanghai Co. patent BRD4/1/2 inhibitors June 7, 2018
S1P regulation key for bone quality and may constitute a therapeutic target in osteoporosis June 7, 2018
RSS